BACKGROUND: We identified the BRK tyrosine kinase in a PCR-based screen of tyrosine kinases expressed by ovarian tumors. BRK expression is restricted to normal differentiating epithelial cells and its overexpression may play a role in processes related to tumor development and growth. Its expression in normal ovary and ovarian tumors has not previously been described, and is the focus of this study. METHODS: BRK expression levels were determined in 14 normal ovaries and 138 high-grade, late stage serous carcinomas of the ovary by immunohistochemical analysis, and in 19 ovarian cancer cell lines and immortalized ovarian surface epithelium by Western blot analysis. Furthermore, BRK/PTK6 gene copy number was determined in seven primary serous carcinomas by fluorescence in situ hybridization. RESULTS: Immunohistochemical studies indicate that BRK is highly expressed in 97/138 (70%) of high-grade, serous carcinomas of the ovary, but is absent in normal ovarian surface epithelia. BRK is also expressed by 9/19 of ovarian cancer cell lines, but is undetectable in immortalized ovarian surface epithelium. Interestingly, the BRK gene has been mapped to chromosome 20q13.3, a site frequently amplified in ovarian cancers, and associated with poor prognosis. We have determined by fluorescence in situ hybridization (FISH) that BRK is specifically amplified at low levels in 6/7 primary ovarian carcinomas. CONCLUSIONS: The amplification of the BRK gene and overexpression of BRK protein in the majority of high-grade serous carcinomas and ovarian cancer cell lines suggest that BRK may play a role in the development and growth of ovarian tumors.
BACKGROUND: We identified the BRK tyrosine kinase in a PCR-based screen of tyrosine kinases expressed by ovarian tumors. BRK expression is restricted to normal differentiating epithelial cells and its overexpression may play a role in processes related to tumor development and growth. Its expression in normal ovary and ovarian tumors has not previously been described, and is the focus of this study. METHODS: BRK expression levels were determined in 14 normal ovaries and 138 high-grade, late stage serous carcinomas of the ovary by immunohistochemical analysis, and in 19 ovarian cancer cell lines and immortalized ovarian surface epithelium by Western blot analysis. Furthermore, BRK/PTK6 gene copy number was determined in seven primary serous carcinomas by fluorescence in situ hybridization. RESULTS: Immunohistochemical studies indicate that BRK is highly expressed in 97/138 (70%) of high-grade, serous carcinomas of the ovary, but is absent in normal ovarian surface epithelia. BRK is also expressed by 9/19 of ovarian cancer cell lines, but is undetectable in immortalized ovarian surface epithelium. Interestingly, the BRK gene has been mapped to chromosome 20q13.3, a site frequently amplified in ovarian cancers, and associated with poor prognosis. We have determined by fluorescence in situ hybridization (FISH) that BRK is specifically amplified at low levels in 6/7 primary ovarian carcinomas. CONCLUSIONS: The amplification of the BRK gene and overexpression of BRK protein in the majority of high-grade serous carcinomas and ovarian cancer cell lines suggest that BRK may play a role in the development and growth of ovarian tumors.
Authors: Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange Journal: Horm Cancer Date: 2012-04 Impact factor: 3.869
Authors: Pablo Vivas-Mejia; Juliana Maria Benito; Ariel Fernandez; Hee-Dong Han; Lingegowda Mangala; Cristian Rodriguez-Aguayo; Arturo Chavez-Reyes; Yvonne G Lin; Mark S Carey; Alpa M Nick; Rebecca L Stone; Hye Sun Kim; Francois-Xavier Claret; William Bornmann; Bryan T J Hennessy; Angela Sanguino; Zhengong Peng; Anil K Sood; Gabriel Lopez-Berestein Journal: Clin Cancer Res Date: 2009-12-22 Impact factor: 12.531
Authors: Hanna Y Irie; Yashaswi Shrestha; Laura M Selfors; Fabianne Frye; Naoko Iida; Zhigang Wang; Lihua Zou; Jun Yao; Yiling Lu; Charles B Epstein; Sridaran Natesan; Andrea L Richardson; Kornelia Polyak; Gordon B Mills; William C Hahn; Joan S Brugge Journal: PLoS One Date: 2010-07-23 Impact factor: 3.240
Authors: Patrick M Brauer; Yu Zheng; Mark D Evans; Carmen Dominguez-Brauer; Donna M Peehl; Angela L Tyner Journal: PLoS One Date: 2011-03-30 Impact factor: 3.240
Authors: Lingtao Jin; Dan Li; Jong Seok Lee; Shannon Elf; Gina N Alesi; Jun Fan; Hee-Bum Kang; Dongsheng Wang; Haian Fu; Jack Taunton; Titus J Boggon; Meghan Tucker; Ting-Lei Gu; Zhuo G Chen; Dong M Shin; Fadlo R Khuri; Sumin Kang Journal: Mol Cell Biol Date: 2013-04-22 Impact factor: 4.272